Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
58
ETON Quote, Financials, Valuation and Earnings
Last price:
$16.56
Seasonality move
:
-2.97%
Day range:
$16.32 - $16.95
52-week range:
$11.09 - $23.00
Dividend yield:
0%
P/E ratio:
92.00x
P/S ratio:
6.29x
P/B ratio:
19.21x
Volume:
147.3K
Avg. volume:
268.8K
1-year change:
31.82%
Market cap:
$444.4M
Revenue:
$39M
EPS (TTM):
-$0.25
Analysts' Opinion
-
Consensus RatingEton Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.00, Eton Pharmaceuticals, Inc. has an estimated upside of 81.05% from its current price of $16.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 100% downside risk from its current price of $16.57.
Fair Value
-
According to the consensus of 3 analysts, Eton Pharmaceuticals, Inc. has 81.05% upside to fair value with a price target of $30.00 per share.
ETON vs. S&P 500
-
Over the past 5 trading days, Eton Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.52% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Eton Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eton Pharmaceuticals, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Eton Pharmaceuticals, Inc. reported revenues of $22.5M.
Earnings Growth
-
Eton Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Eton Pharmaceuticals, Inc. reported earnings per share of -$0.07.
Enterprise value:
438.1M
EV / Invested capital:
8.11x
Price / LTM sales:
6.29x
EV / EBIT:
152.95x
EV / Revenue:
6.23x
PEG ratio (5yr expected):
-3.99x
EV / Free cash flow:
33.98x
Price / Operating cash flow:
34.31x
Enterprise value / EBITDA:
271.79x
Gross Profit (TTM):
$36.1M
Return On Assets:
-8.31%
Net Income Margin (TTM):
-9.5%
Return On Equity:
-29.85%
Return On Invested Capital:
-14.04%
Operating Margin:
-5.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $32.8M | $34.7M | $70.3M | $10.3M | $22.5M | |
| Gross Profit | $23.8M | $20.6M | $36.1M | $6.3M | $7.9M | |
| Operating Income | $1.9M | -$5.2M | -$1.8M | $509K | -$1.2M | |
| EBITDA | $2.7M | -$4.1M | $1.6M | $788K | -$164K | |
| Diluted EPS | $0.08 | -$0.21 | -$0.25 | $0.02 | -$0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $25.9M | $16.4M | $27.2M | $29.7M | $72M | |
| Total Assets | $26.6M | $21.5M | $31.5M | $35.8M | $104.5M | |
| Current Liabilities | $5.4M | $4.7M | $10.4M | $19.7M | $44.2M | |
| Total Liabilities | $10.9M | $10.3M | $14.6M | $19.9M | $81.4M | |
| Total Equity | $15.7M | $11.2M | $16.9M | $16M | $23.1M | |
| Total Debt | $6.7M | $6.4M | $5.8M | $4.3M | $30.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.3M | $2.1M | $21.3M | $3M | $12M | |
| Cash From Investing | -$12K | -$2.7M | -$38.4M | -- | -$284K | |
| Cash From Financing | -$564K | -$1.3M | $34M | -$385K | -- | |
| Free Cash Flow | $9.3M | -$536K | $12.9M | $3M | $11.7M | |
ETON
Sector
Market Cap
$444.4M
$28.4M
Price % of 52-Week High
72.04%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-2.34%
-1.49%
1-Year Price Total Return
31.82%
-16.67%
Beta (5-Year)
1.172
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.28
200-day SMA
Buy
Level
$16.48
Bollinger Bands (100)
Sell
Level
16.05 - 19.21
Chaikin Money Flow
Buy
Level
1.1M
20-day SMA
Buy
Level
$16.21
Relative Strength Index (RSI14)
Sell
Level
49.85
ADX Line
Buy
Level
12.08
Williams %R
Neutral
Level
-34.6369
50-day SMA
Sell
Level
$17.25
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
34.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.895)
Sell
CA Score
(Annual)
Level (-0.9607)
Sell
Beneish M-Score
(Annual)
Level (-1.5083)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.3005)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.
Stock Forecast FAQ
In the current month, ETON has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ETON average analyst price target in the past 3 months is $30.00.
-
Where Will Eton Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eton Pharmaceuticals, Inc. share price will rise to $30.00 per share over the next 12 months.
-
What Do Analysts Say About Eton Pharmaceuticals, Inc.?
Analysts are divided on their view about Eton Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eton Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Eton Pharmaceuticals, Inc.'s Price Target?
The price target for Eton Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $30.00 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ETON A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eton Pharmaceuticals, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ETON?
You can purchase shares of Eton Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eton Pharmaceuticals, Inc. shares.
-
What Is The Eton Pharmaceuticals, Inc. Share Price Today?
Eton Pharmaceuticals, Inc. was last trading at $16.56 per share. This represents the most recent stock quote for Eton Pharmaceuticals, Inc.. Yesterday, Eton Pharmaceuticals, Inc. closed at $16.57 per share.
-
How To Buy Eton Pharmaceuticals, Inc. Stock Online?
In order to purchase Eton Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ETON Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ETON
Sector
P/E ratio
92.00x
23.89x
PEG ratio
-3.99x
-0.01x
P/B ratio
19.21x
1.81x
Price / LTM sales
6.29x
1.58x
Growth Metrics
ETON
Sector
Revenue growth
117.54%
4.62%
Earnings growth
-403.39%
10.7%
Revenue (5-year growth)
109.83%
6.5%
Earnings forecast
$0.16
-$0.21
Profitability
ETON
Sector
Profitability FY 2024
$23.4M
$3.6M
Return on invested capital
-14.04%
-31.84%
Return on assets
-8.31%
-27.96%
Return on equity
-29.85%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
5
Balance Sheet
ETON
Sector
Total cash
$37.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$76.1M
$76.9M
Long term debt
$30.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
